Lympro Chem Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 30-07-2024
- Paid Up Capital ₹ 1.00 Cr
as on 30-07-2024
- Company Age 20 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.01 Cr
as on 30-07-2024
- Revenue 11.12%
(FY 2023)
- Profit -27652.09%
(FY 2023)
- Ebitda -999.99%
(FY 2023)
- Net Worth -110.98%
(FY 2023)
- Total Assets -25.97%
(FY 2023)
About Lympro Chem
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹3.01 Cr.
Padmakar Saraf and Mangesh Saraf serve as directors at the Company.
- CIN/LLPIN
U24100MH2004PTC145403
- Company No.
145403
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Mar 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Lympro Chem Private Limited offer?
Lympro Chem Private Limited offers a wide range of products and services, including Rubber & Rubber Products, Synthetic Rubbers, Rust & Corrosion Protection Products, Anti Corrosion Coating, FRP Lining, PU & Powder Coatings, PU Paints and Coatings, PET Granules & Plastic Raw Material, Plastic Polymers, PU Foam, Coir & Jute Mattresses, Foam Sheet.
Who are the key members and board of directors at Lympro Chem?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Padmakar Saraf  | Director | 29-Mar-2004 | Current |
| Mangesh Saraf | Director | 29-Mar-2004 | Current |
Financial Performance of Lympro Chem.
Lympro Chem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.12% increase. The company also saw a substantial fall in profitability, with a 27652.09% decrease in profit. The company's net worth observed a substantial decline by a decrease of 110.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lympro Chem?
In 2023, Lympro Chem had a promoter holding of 37.00% and a public holding of 63.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Feb 2020 | ₹2.30 M | Open |
Dombivli Nagari Sahakari Bank Ltd. Creation Date: 09 Nov 2010 | ₹3.00 M | Open |
Dombivli Nagari Sahakari Bank Ltd. Creation Date: 04 Nov 2010 | ₹9.00 M | Open |
How Many Employees Work at Lympro Chem?
Unlock and access historical data on people associated with Lympro Chem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lympro Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lympro Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
